Format

Send to

Choose Destination
Dermatol Clin. 2004 Apr;22(2):213-9.

Dysport.

Author information

1
St. John's Institute of Dermatology, St. Thomas' Hospital, London SE17EH, UK. markeyoffice@aol.com

Abstract

Since the commercial launch of Dysport in 1991, after 10 years of clinical studies on its predecessor formulations, this BTX-A product has shown great therapeutic promise with a good safety profile and low incidence of treatment failures. As with all BTX products, Dysport should not be seen as a generic equivalent but as a specific product with individual unit dosing requirements and side effect profiles. Its role as an important BTX-A molecule looks set to expand as new indications for botulinum toxin arise, and as the cosmetic usage of Dysport is approved in countries outside of South America.

PMID:
15222582
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center